Submit a comment

Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease: With observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor
Theodore S. Zimmerman, … , Oscar D. Ratnoff, Arnold E. Powell
Theodore S. Zimmerman, … , Oscar D. Ratnoff, Arnold E. Powell
Published January 1, 1971
Citation Information: J Clin Invest. 1971;50(1):244-254. https://doi.org/10.1172/JCI106480.
View: Text | PDF
Article has an altmetric score of 6

Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease: With observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor

Abstract

Heterologous antiserum was prepared in rabbits against highly purified human antihemophilic factor (AHF, factor VIII). This antiserum blocked the clot-promoting properties of AHF and, when suitably absorbed, formed a single precipitin line against AHF upon immunoelectrophoresis. Material antigenically similar to normal AHF was detected in normal amounts in plasma concentrates in each of 22 patients with classic hemophilia, in a patient with an acquired circulating anticoagulant against AHF, and in a patient with deficiencies both of AHF and proaccelerin (factor V). AHF-like antigen was present in normal human serum. In contrast, material antigenically related to AHF was found in decreased amounts in the concentrates prepared from the plasma of 11 patients with von Willebrand's disease. The experiments described suggest that von Willebrand's disease is a disorder in which a true deficiency of AHF exists. Whether the AHF-like material found in classic hemophilia is nonfunctional through a defect in structure or through the intervention of an inhibitor has not been shown.

Authors

Theodore S. Zimmerman, Oscar D. Ratnoff, Arnold E. Powell

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
Rich Text Editor, eletter_body